ArticleThe British journal of psychiatry : the journal of mental science2024
Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials.
Article in The British journal of psychiatry : the journal of mental science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Metabolic Status Influences Probiotic Efficacy for Depression-PRO-DEMET Randomized Clinical Trial Results.Nutrients · 2024Trial
- Mental health in elite athletes: International Olympic Committee consensus statement (2026).British journal of sports medicine · 2026Article
- [Inflammatory depression: a review of advances in pathophysiology, clinical implications, and treatment].Revista medica del Instituto Mexicano del Seguro Social · 2026Review
- Atypical energy-related symptoms define biologically distinct subtypes of major depressive disorder.medRxiv : the preprint server for health sciences · 2026Article
- Relationship between triglyceride glucose-waist circumference and depressive symptoms in Chinese older adults: The China health and retirement longitudinal study.Brain, behavior, & immunity - health · 2026Article
- A multimodal approach to depression diagnosis: insights from machine learning algorithm development in primary care.European archives of psychiatry and clinical neuroscience · 2026Article
- [Immunometabolic mechanisms in atypical depression].Der Nervenarzt · 2026Review
- Machine learning for immune biomarkers in severe mental illness: a systematic review.Neuroscience applied · 2026Review
- The kynurenine pathway in depression and schizophrenia: convergent signals, divergent states, and clinical signatures.EXCLI journal · 2026Review
- Immunometabolic reprogramming of central and peripheral immune cells in mental disorders: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- The moderating role of diet and physical activity in insulin resistance and immunometabolic depression.Scientific reports · 2025Article
- Towards precision psychiatry: Metabolomics identifies three biological subtypes of depression.PLOS digital health · 2025Article
- Discovery of Personalized Treatment for Immuno-Metabolic Depression-Focus on 11beta Hydroxysteroid Dehydrogenase Type 2 (11betaHSD2) and Toll-like Receptor 4 (TLR4) Inhibition with Enoxolone.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Precision psychiatry roadmap: towards a biology-informed framework for mental disorders.Molecular psychiatry · 2025Review
- Advancing an Inflammatory Subtype of Major Depression.The American journal of psychiatry · 2025Review
- Lipids and C-reactive protein predict anhedonia and reward circuit functional connectivity responses to anti-cytokine and dopaminergic therapies in patients with depression.Comprehensive psychoneuroendocrinology · 2025Article
- Immuno-metabolic depression: from concept to implementation.The Lancet regional health. Europe · 2025Review
- Metabolic regulation of the immune system in health and diseases: mechanisms and interventions.Signal transduction and targeted therapy · 2024Review
- Advancements, challenges and future horizons in personalized psychiatry.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 7 countries.
Funding
Abstract
backgroundProfiling patients on a proposed 'immunometabolic depression' (IMD) dimension, described as a cluster of atypical depressive symptoms related to energy regulation and immunometabolic dysregulations, may optimise personalised treatment.
aimsTo test the hypothesis that baseline IMD features predict poorer treatment outcomes with antidepressants.
methodData on 2551 individuals with depression across the iSPOT-D (
resultsAlthough AES severity and BMI did not predict changes in depressive symptom severity, higher baseline CRP predicted smaller reductions in depressive symptoms (
conclusionsDepressive symptoms of people with more IMD features improved less when treated with antidepressants. However, clinical relevance is limited owing to small effect sizes in inconsistent associations. Whether these patients would benefit more from treatments targeting immunometabolic pathways remains to be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.